ArticleFrontiers in aging2026
PCKP versus UPKP for moderate-to-severe osteoporotic vertebral compression fractures: a prospective randomized controlled trial revealing synergistic mechanisms of optimized bone cement distribution and anti-osteoporosis therapy on medium-to-long-term outcomes.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Percutaneous curved kyphoplasty (PCKP) demonstrates early advantages in treating osteoporotic vertebral compression fractures (OVCFs), but its long-term efficacy and patient-selection criteria remain controversial. Objective: The aim of this study is to prospectively compare the mid-to-long-term outcomes of PCKP versus unilateral percutaneous kyphoplasty (UPKP) for single-level OVCFs and establish a hierarchical decision model based on vertebral compression severity. Methods: A total of 139 patients with single-level OVCFs (January 2021-January 2023) were randomized to PCKP (n = 67) or UPKP (n = 72), with ≥24-month follow-up. Outcomes included the visual analog score (VAS), Oswestry dysfunction index (ODI), cement distribution (type I-V classification), leakage rate, and re-fracture incidence. Anti-osteoporosis compliance was analyzed for its impact on efficacy. Results: Both groups showed significant postoperative improvement in VAS and ODI ( Conclusion: PCKP enhances early biomechanical stability in moderate-to-severe OVCFs through optimized cement dispersion, while long-term efficacy relies on standardized anti-osteoporosis therapy. A stepwise decision model ("PCKP for Genant 2-3, UPKP for mild cases"), combined with a "vertebral augmentation-bone metabolism modulation-behavioral intervention" strategy, is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.